Resistance and barriers to local estrogen therapy in women with atrophic vaginitis

Journal of Sexual Medicine

Volumn 10, Issue 6, 2013, Pages 1567-1574

  Kingsberg, Sheryl A ^a   Krychman, Michael L ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Southern California Center for Sexual Health and Survivorship Medicine   (United States)

Author keywords

Communication; Local Estrogen Therapy; Patient Education; Postmenopausal Women; Vaginal Atrophy

Indexed keywords

ESTROGEN; LUBRICATING AGENT;

ARTICLE; ATROPHIC VAGINITIS; COMMUNICATION SKILL; DRUG SAFETY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; LUBRICATION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREMENOPAUSE; PRIORITY JOURNAL; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VAGINA MUCOSA;

EID: 84878741837     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12120     Document Type: Article

References (27)

1. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:355-369; quiz 70-1.
2. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509-522.
3. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133-2142.
4. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15:661-666.
5. Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: Results from an international survey on vaginal atrophy. Maturitas 2010;67:233-238.
6. Pinkerton JV. Vaginal impact of menopause-related estrogen deficiency. OBG Manag 2010;(suppl):S2-7.
7. Krychman M. Impact of vaginal atrophy on quality of life and sexuality. OBG Manag 2010;(suppl):S14-19.
8. Goldstein I. Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health (Larchmt) 2010;19:425-432.
9. Bachmann G. Urogenital ageing: An old problem newly recognized. Maturitas 1995;22(suppl):S1-5.
10. Nappi RE, Polatti F. The use of estrogen therapy in women's sexual functioning (CME). J Sex Med 2009;6:603-616; quiz 18-9.
11. Barlow DH, Samsioe G, Van Geelen JM. A study of European womens' experience of the problems of urogenital ageing and its management. Maturitas 1997;27:239-247.
12. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA)-Results from an international survey. Climacteric 2012;15:36-44.
13. Kagan R. Therapeutic options for the treatment of vaginal atrophy. OBG Manag 2010;(suppl):S8-13.
14. Lehman RA. Clinical approach to recognizing and managing a patient with vaginal atrophy: A guide for physician assistants. Internet J Acad Physician Assist 2010;1(8). Sugar Land, Texas: Internet Scientific Publications.
15. Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194-203.
16. Ibe C, Simon JA. Vulvovaginal atrophy: Current and future therapies (CME). J Sex Med 2010;7:1042-1050; quiz 51.
17. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-271.
18. Kingsberg S, Kellogg S, Krychman M. Treating dyspareunia caused by vaginal atrophy: A review of treatment options using vaginal estrogen therapy. Int J Womens Health 2010;1:105-111.
19. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000;61:3090-3096.
20. Freeman SB. Tissue changes associated with vaginal atrophy. Clin Advis 2010;9(13):32-38.
21. Lara LA, Useche B, Ferriani RA, Reis RM, de Sa MF, de Freitas MM, Rosa e Silva JC, Rosa e Silva AC. The effects of hypoestrogenism on the vaginal wall: Interference with the normal sexual response. J Sex Med 2009;6:30-39.
22. Krychman ML. Vaginal estrogens for the treatment of dyspareunia. J Sex Med 2011;8:666-674.
23. American College of Obstetricians and Gynecologists, Women's Health Care Physicians. Hormone therapy. Sexual dysfunction. Obstet Gynecol 2004;104:S85-91.
24. Langer RD. Efficacy, safety, and tolerability of low-dose hormone therapy in managing menopausal symptoms. J Am Board Fam Med 2009;22:563-573.
25. Pfizer Pharmaceuticals Inc. REVEAL REvealing Vaginal Effects At mid-Life: Surveys of postmenopausal women and health care professionals who treat postmenopausal women. REVEAL Web site. 2009. Available at: http://www.revealsurvey.com/pdf/reveal-survey-results.pdf (accessed November 8, 2012) (vol 2012).
26. Pfizer Pharmaceuticals Inc. Healthy women survey. Personal Menopause Web site. 2011 (vol 2012).
27. Simon JA. The partners' survey; impact of vaginal discomfort and its treatment-Insights, views, and attitudes of postmenopausal women and their partners. 23rd Annual Meeting of The North American Menopause Society. Orlando, FL, 2012.